HUE066288T2 - Paclitaxel-hialuronsav konjugátum nem-izom invazív húgyhólyagrák kezelésében - Google Patents

Paclitaxel-hialuronsav konjugátum nem-izom invazív húgyhólyagrák kezelésében

Info

Publication number
HUE066288T2
HUE066288T2 HUE19801630A HUE19801630A HUE066288T2 HU E066288 T2 HUE066288 T2 HU E066288T2 HU E19801630 A HUE19801630 A HU E19801630A HU E19801630 A HUE19801630 A HU E19801630A HU E066288 T2 HUE066288 T2 HU E066288T2
Authority
HU
Hungary
Prior art keywords
paclitaxel
treatment
hyaluronic acid
bladder cancer
acid conjugate
Prior art date
Application number
HUE19801630A
Other languages
English (en)
Hungarian (hu)
Inventor
Giorgio Mosconi
Daniela Jabes
Carlo Pizzocaro
Original Assignee
Fidia Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia Farm Spa filed Critical Fidia Farm Spa
Publication of HUE066288T2 publication Critical patent/HUE066288T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE19801630A 2018-10-25 2019-10-23 Paclitaxel-hialuronsav konjugátum nem-izom invazív húgyhólyagrák kezelésében HUE066288T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102018000009731A IT201800009731A1 (it) 2018-10-25 2018-10-25 Coniugato paclitaxel - acido ialuronico nel trattamento del carcinoma vescicale non infiltrante

Publications (1)

Publication Number Publication Date
HUE066288T2 true HUE066288T2 (hu) 2024-07-28

Family

ID=65324453

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE19801630A HUE066288T2 (hu) 2018-10-25 2019-10-23 Paclitaxel-hialuronsav konjugátum nem-izom invazív húgyhólyagrák kezelésében

Country Status (21)

Country Link
US (4) US20200397909A1 (enExample)
EP (1) EP3870233B1 (enExample)
JP (1) JP7518815B2 (enExample)
KR (1) KR102913965B1 (enExample)
CN (2) CN119792555A (enExample)
CA (1) CA3112188A1 (enExample)
DK (1) DK3870233T3 (enExample)
EA (1) EA202190614A1 (enExample)
ES (1) ES2971217T3 (enExample)
FI (1) FI3870233T3 (enExample)
HR (1) HRP20240188T1 (enExample)
HU (1) HUE066288T2 (enExample)
IT (1) IT201800009731A1 (enExample)
LT (1) LT3870233T (enExample)
MA (1) MA63879B1 (enExample)
PL (1) PL3870233T3 (enExample)
PT (1) PT3870233T (enExample)
RS (1) RS65193B1 (enExample)
SI (1) SI3870233T1 (enExample)
SM (1) SMT202400021T1 (enExample)
WO (1) WO2020084525A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000007747A1 (it) * 2020-04-10 2021-10-10 Fidia Farm Spa Coniugato acido ialuronico-paclitaxel nel trattamento del mesotelioma
IT202000008209A1 (it) * 2020-04-17 2021-10-17 Fidia Farm Spa Procedimento di sintesi di un coniugato acido ialuronico-paclitaxel

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2553099B1 (fr) 1983-10-11 1989-09-08 Fidia Spa Fractions d'acide hyaluronique ayant une activite pharmaceutique, procedes pour leur preparation et compositions pharmaceutiques les contenant
IT1263393B (it) 1993-07-30 1996-08-05 Fidia Advanced Biopolymers Srl Processo per la preparazione e purificazione di acido ialuronico ad alto peso molecolare
NZ516873A (en) 2001-02-12 2003-11-28 Warner Lambert Co Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage
ITPD20020271A1 (it) * 2002-10-18 2004-04-19 Fidia Farmaceutici Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.
AR047938A1 (es) * 2003-08-25 2006-03-15 Combinatorx Inc Formulaciones, conjugados y combinaciones de farmacos para el tratamiento de neoplasmas
ITMI20071267A1 (it) 2007-06-22 2008-12-23 Fidia Farmaceutici Uso di coniugati dell'acido ialuronico nel trattamento locale di malattie cutanee iperproliferative
IT1402384B1 (it) 2010-09-09 2013-09-04 Fidia Farmaceutici Processo per la produzione di acido ialuronico in escherichia coli o bacillus megaterium
IT1402385B1 (it) 2010-09-09 2013-09-04 Fidia Farmaceutici Processo per la produzione di acido ialuronico in escherichia coli o bacillus subtilis
ES2653679T3 (es) 2011-11-09 2018-02-08 Spinalcyte, Llc Fibroblastos dérmicos para el tratamiento de enfermedad discal degenerativa
IT201600079633A1 (it) 2016-07-28 2018-01-28 Fidia Farm Spa Procedimento di preparazione e purificazione del sale sodico dell’acido ialuronico
CN110859962B (zh) 2019-11-25 2021-01-22 山东大学 巴比妥酸衍生物修饰的二硫化钼二维纳米材料及其应用

Also Published As

Publication number Publication date
ES2971217T3 (es) 2024-06-04
KR102913965B1 (ko) 2026-01-16
IT201800009731A1 (it) 2020-04-25
JP2022503771A (ja) 2022-01-12
EP3870233B1 (en) 2023-12-06
FI3870233T3 (fi) 2024-02-07
LT3870233T (lt) 2024-02-26
SMT202400021T1 (it) 2024-03-13
PT3870233T (pt) 2024-02-01
DK3870233T3 (da) 2024-02-05
JP7518815B2 (ja) 2024-07-18
US20240123077A1 (en) 2024-04-18
CN119792555A (zh) 2025-04-11
EA202190614A1 (ru) 2021-06-03
PL3870233T3 (pl) 2024-05-06
CA3112188A1 (en) 2020-04-30
US20210268119A1 (en) 2021-09-02
KR20210083249A (ko) 2021-07-06
US12465649B2 (en) 2025-11-11
EP3870233A1 (en) 2021-09-01
HRP20240188T1 (hr) 2024-05-10
CN112805035A (zh) 2021-05-14
RS65193B1 (sr) 2024-03-29
WO2020084525A1 (en) 2020-04-30
SI3870233T1 (sl) 2024-03-29
MA63879B1 (fr) 2024-02-29
US20200397909A1 (en) 2020-12-24
US20210196833A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
IL273550A (en) Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the I148M variant of PNPLA3
IL290415A (en) Compounds with deuterium for use in cancer treatment
HRP20180876T1 (hr) Adc duokarmicina, namijenjeni upotrebi u liječenju raka mokraćnog mjehura
SMT202300418T1 (it) Trattamento di tumori positivi per lag-3
SI3806898T1 (sl) Antagonist Gremlin-1 za uporabo pri zdravljenju raka
IL276406A (en) Osimertinib for use in the treatment of non-small cell lung cancer
LT3532067T (lt) Liposominė vaisto forma, skirta naudoti gydant vėžį
PL3886579T5 (pl) Leczenie narządu ex vivo cząsteczkami peg-fosfolipidu
PL4340842T3 (pl) Sotorasib do zastosowania w leczeniu nowotworów
HUE066288T2 (hu) Paclitaxel-hialuronsav konjugátum nem-izom invazív húgyhólyagrák kezelésében
SG11202007005UA (en) Use of crassocephalum rabens extract in the treatment of breast cancer
IL269121A (en) Usl-311 for use in the treatment of cancer
SG11202105276TA (en) Oligo-benzamide analogs and their use in cancer treatment
SG11202011434SA (en) Methods for the treatment of bladder cancer
ZA202001435B (en) Abx196 for use in the treatment of bladder cancer
HUE065202T2 (hu) Készítmény bélelváltozások kezelésében való felhasználásra
HK40064163A (en) Oligo-benzamide analogs and their use in cancer treatment
HK40025688A (en) Cobitolimod for use in the treatment of inflammatory bowel disease
HK40018432A (en) Usl-311 for use in the treatment of cancer
GB201609690D0 (en) Therapeutic use of norfluxetine in breast cancer treatment